Skip to main content
Equibles
NUTX logo

NUTX · Nutex Health Inc. · Webcasts, Transcripts & Audio

Track NUTX — free

Use NUTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NUTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$211.67 +3.42 (+1.64%) Q1 2026 earnings call transcript
Russell 2000 member Rebalance outlook locked
Market Cap
$1.43B
Shares
6.85M
Volume · Oct 28 120.07K Avg daily vol (3M) 155.64K

Nutex Health Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Nutex Health Inc. (NUTX), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Earnings call
FY26 · Q2
2026-08-07
Nutex Health Inc. (NUTX) Q2 2026 Earnings Call
Revenue
$210.75M
▼ 13.6% YoY
Diluted EPS
$9.38
Gross margin
67.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-01
Nutex Health Inc. (NUTX) Q1 2026 Earnings Call Transcript
Confident tone IPA / Population Health segment IDR / payer reimbursement and No Surprises Act Revenue and earnings performance
Revenue
$216.49M
▲ 2.2% YoY
Diluted EPS
$6.52
▲ 95.8% YoY
Gross margin
42.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-06
Nutex Health Inc. (NUTX) Q4 2025 Earnings Call Transcript
Confident tone IDR arbitration and No Surprises Act Hospital expansion pipeline Revenue and earnings growth
Revenue
$151.68M*
▼ 41.1% YoY
Gross margin
30.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q2
2025-08-14
Nutex Health Inc. (NUTX) Q2 2025 Earnings Call Transcript
Confident tone No Surprises Act / IDR Arbitration Strategy Financial Performance and Growth Mature Hospital Performance and Patient Acuity
Revenue
$243.99M
▲ 220.7% YoY
Diluted EPS
$-2.95
Gross margin
51.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Nutex Health Inc. (NUTX) Q1 2025 Earnings Call Transcript
Confident tone Balance sheet and capital allocation Patient volume and acuity mix Arbitration process and IDR revenue
Revenue
$211.79M
▲ 214% YoY
Diluted EPS
$3.33
Gross margin
55.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-31
Nutex Health Inc. (NUTX) Q4 2024 Earnings Call Transcript
Confident tone Arbitration / IDR process success No Surprises Act challenges Revenue and EBITDA growth
Revenue
$257.62M
▲ 269.8% YoY
Diluted EPS
$11.12
Gross margin
55.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Nutex Health Inc. (NUTX) Q3 2024 Earnings Call Transcript
Confident tone Revenue and patient volume growth De novo hospital expansion pipeline No Surprises Act and IDR reimbursement
Revenue
$78.80M
▲ 25.6% YoY
Diluted EPS
$-1.72
Gross margin
27.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Nutex Health Inc. (NUTX) Q2 2024 Earnings Call Transcript
Confident tone Population Health / IPAs Micro-Hospital Business Model No Surprises Act Arbitration
Revenue
$76.08M
▲ 29.1% YoY
Diluted EPS
$-0.07
Gross margin
29.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Nutex Health Inc. (NUTX) Q1 2024 Earnings Call Transcript
Confident tone No Surprises Act Collections & Reimbursement Population Health / Medicare Advantage (MA) Lives Earnings Growth & Financial Performance
Revenue
$67.45M
▲ 19.7% YoY
Diluted EPS
$-0.08
Gross margin
15.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–9 of 9 webcasts
Key facts CIK 1479681 CUSIP 67079U306 13F (30d) 22 filings 22 filers Visit website Investor relations